Dow Jones

39,065.26

-1.53%

Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

Regístrate

Inicio
Invertir
Acciones
Estados Unidos
NASDAQ
Transgene S.A. ADS (MM) (TRGNY)
Transgene S.A. ADS (MM) (TRGNY) Noticias

TRGNY

Transgene . (TRGNY)

Transgene S.A. ADS (MM)

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:TRGNY

Fecha	Hora	Fuente	Título	Símbolo	Compañía
19/10/2005	01:00	PR Newswire (US)	Transgene : Cash Position and Net Cash Expenditures as of September 30, 2005	NASDAQ:TRGNY
21/09/2005	00:01	PR Newswire (US)	Transgene to Voluntarily Delist From Nasdaq	NASDAQ:TRGNY
03/08/2005	00:01	PR Newswire (US)	Transgene Announces First Half 2005 Financial Results	NASDAQ:TRGNY
21/07/2005	00:01	PR Newswire (US)	Transgene Announces Achievement of Clinical Milestone by Merck & Co., Inc. Using Transgene's Proprietary Technology	NASDAQ:TRGNY
11/07/2005	12:01	PR Newswire (US)	Transgene Raises Euro 34.9 Million	NASDAQ:TRGNY
20/05/2005	00:01	PR Newswire (US)	Transgene Announces 20-F Form Filing	NASDAQ:TRGNY
17/05/2005	00:01	PR Newswire (US)	Transgene's Therapeutic Vaccine MVA-MUC1-IL2 at ASCO:	NASDAQ:TRGNY
16/05/2005	00:01	PR Newswire (US)	Transgene Presents Updated Positive Phase II Data of Its Therapeutic Vaccine MVA-MUC1-IL2 In Prostate Cancer at Annual ASCO Meet	NASDAQ:TRGNY
26/04/2005	00:01	PR Newswire (US)	Transgene to Present at the 2nd Rodman & Renshaw Annual Global Healthcare Conference	NASDAQ:TRGNY
13/04/2005	00:01	PR Newswire (US)	Transgene: Cash Position and Net Cash Expenditures as of March 31, 2005	NASDAQ:TRGNY
05/04/2005	00:01	PR Newswire (US)	Transgene to Present Phase II Data of Its MVA-UC1-IL2 Cancer Vaccine at ASCO's 2005 Annual Meeting	NASDAQ:TRGNY
23/02/2005	00:00	PR Newswire (US)	Transgene Announces Fiscal Year 2004 Financial Results	NASDAQ:TRGNY
23/02/2005	00:00	PR Newswire (US)	Transgene: New Strategy in Therapeutic Vaccines, MVA-Muc1-IL2 Meets Primary Endpoint in Lung Cancer Phase II	NASDAQ:TRGNY
14/02/2005	23:01	PR Newswire (US)	Transgene Appoints Jean-Yves Bonnefoy as New Chief Scientific Officer	NASDAQ:TRGNY
07/12/2004	23:01	PR Newswire (US)	Transgene Appoints Philippe Archinard As New Chief Executive Officer	NASDAQ:TRGNY
30/11/2004	10:34	PR Newswire (US)	Transgene Moves Forward Its Vaccine Candidate MVA-HPV-IL2 In A Novel Approach Against Pre-Cancerous Cervical Lesions	NASDAQ:TRGNY
02/11/2004	23:01	PR Newswire (US)	Transgene: Cash Position and Net Cash Expenditures as of September 30, 2004	NASDAQ:TRGNY
04/08/2004	00:01	PR Newswire (US)	Transgene Announces Second Quarter and First Half 2004 Financial Results	NASDAQ:TRGNY
01/07/2004	08:31	PR Newswire (US)	Transgene Manufactures Clinical Lots of HIV Vaccine Candidates for the EUROVAC Project	NASDAQ:TRGNY
15/06/2004	01:00	PR Newswire (US)	Merial and Transgene Sign a Collaboration Agreement to Develop Products for Animal Health	NASDAQ:TRGNY	Transgene S.A. ADS (MM)
08/06/2004	00:01	PR Newswire (US)	Transgene Presents Data on MVA-MUC1-IL2 Cancer Vaccine at ASCO and ASGT Annual Meetings	NASDAQ:TRGNY
12/05/2004	08:45	PR Newswire (US)	Transgene to Present Data at 2004 ASCO Annual Meeting	NASDAQ:TRGNY
05/05/2004	00:01	PR Newswire (US)	Transgene Announces First Quarter 2004 Financial Results	NASDAQ:TRGNY
14/04/2004	00:01	PR Newswire (US)	Transgene: Data Presented at The American Association of Cancer Research Annual Meeting Suggest Significant Opportunities for An	NASDAQ:TRGNY
17/03/2004	23:01	PR Newswire (US)	Transgene's MVA-HPV-IL2 Vaccine Shows Activity in Phase II Clinical Trial	NASDAQ:TRGNY
10/02/2004	23:01	PR Newswire (US)	Transgene Announces Fourth Quarter and Fiscal Year 2003 Financial Results	NASDAQ:TRGNY
08/02/2004	23:00	PR Newswire (US)	Transgene Reports Positive Interim Phase II Data from MVA-Muc1-IL2 Cancer Vaccine Program	NASDAQ:TRGNY
04/11/2003	23:01	PR Newswire (US)	Transgene Announces Third Quarter 2003 Financial Results	NASDAQ:TRGNY
02/11/2003	23:01	PR Newswire (US)	Transgene Signs Pre-Clinical AIDS Vaccine Manufacturing Agreement With ANRS and INSERM	NASDAQ:TRGNY